This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor:
—May I call a few points to your attention in connection with your recent editorial "Cardiac Glycosides and Glaucoma" (Arch. Ophthal. 68:155-156, 1962). First, on mechanism of action: the best evidence to date suggests that these digitalis drugs interfere directly with the enzymatic transport of sodium and potassium, probably by competitive inhibition of potassium binding on the external surface of the cell. They do not alter ATP production. Other drugs which do inhibit ATP synthesis (e.g., DNP) may indirectly affect the transport system, which has a high specificity for ATP as its energy source.Second, on your suggestion of wide clinical trial for the cardiac glycosides in glaucoma, it is my feeling that their hazardous toxicology demands great caution, but they may find a place in selected cases of medically and surgically refractory glaucomas, particularly the congenital glaucomas. With careful regulation of dosage, I have been able
Simon KA. ANENT CARDIAC GLYCOSIDES AND GLAUCOMA. Arch Ophthalmol. 1962;68(5):718. doi:10.1001/archopht.1962.00960030722025
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.